This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Knostman, K. A. B. Articles by Capen, C. C. Search for Related Content PubMed PubMed Citation Articles by Knostman, K. A. B. Articles by Capen, C. C. Social Bookmarking                            What's this?

Genetic Alterations in Thyroid Cancer: The Role of Mouse Models

Departments of Veterinary Biosciences (KABK, CCC) and Physiology and Cell Biology (SMJ), The Ohio State University, Columbus, OH

	Abstract

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Thyroid carcinomas are the most common endocrine neoplasms in humans, with a globally increasing incidence. Thyroid follicular cells and neuroendocrine (parafollicular) C cells are each susceptible to neoplastic transformation, resulting in thyroid cancers of differing phenotypes with unique associated genetic mutations and clinical outcomes. Over the past 15 years, several sophisticated genetically engineered mouse models of thyroid cancer have been created to further our understanding of the genetic events leading to thyroid carcinogenesis in vivo. The most significant mouse models of papillary, follicular, anaplastic, and medullary thyroid carcinoma are highlighted, with particular emphasis on the relationship between the relevant oncogenes in these models and genetic events in the naturally occurring human disease. Limitations of each model are presented, and the need for additional models to better recapitulate certain aspects of the human disease is discussed.

Key words: endocrine; mice; Neoplasm; thyroid.

Thyroid carcinomas are the most common endocrine neoplasms in humans, affecting approximately 1% of the population.⁷⁷ Roughly 95% of all thyroid tumors are of thyroid follicular epithelial cell origin, including papillary, follicular, and anaplastic thyroid carcinomas. The remaining 5% are medullary thyroid carcinomas of C cell origin.^17,77 The subclassification of thyroid cancers into these 4 categories is clinically significant. Papillary thyroid carcinomas metastasize via lymphatics to local lymph nodes in an estimated 50% of cases but have the most favorable prognosis, with a 98% 10-year survival rate. Follicular and tall cell variants of papillary thyroid carcinoma are associated with poorer prognoses. Follicular thyroid carcinomas are more prevalent in areas of dietary iodine deficiency, metastasize hematogenously, and are less likely than papillary thyroid carcinomas to take up radioactive iodide for imaging and therapeutic ablation. However, the 10-year survival rate for follicular thyroid carcinomas is still high at 92%. Anaplastic thyroid carcinomas are almost invariably fatal as a result of rapid invasion of critical structures in the neck, distant metastases, and a failure to take up radioactive iodide. In many cases, anaplastic thyroid carcinomas arise from dedifferentiation of follicular or papillary carcinomas or in patients with a history of multinodular goiter.¹⁷

Medullary thyroid carcinomas, also commonly known as C-cell carcinomas, arise from calcitonin-secreting C cells and are associated with inherited syndromes, such as multiple endocrine neoplasia (MEN), in approximately 20%–25% of cases.^17,77 Medullary carcinomas frequently metastasize via the bloodstream, in addition to lymphatic spread, and are treated with surgical resection and/or external beam radiation. In contrast to follicular-origin thyroid tumors, C cells and tumors arising from them do not have the ability to take up radioactive iodide. The 5-year survival rate for medullary thyroid carcinomas is approximately 50%. According to the National Cancer Institute Surveillance Epidemiology and End Results (SEER) data, as well as other studies, thyroid cancer is one of the few cancer types with increasing incidence in the United States and around the globe, particularly among women.⁷⁶

	Genetic Events in Thyroid Tumors of Follicular Cell Origin

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Thyroid follicular cells are responsible for iodide uptake and thyroid hormone synthesis and can undergo neoplastic transformation to carcinomas of 3 histotypes: papillary, follicular, and anaplastic. It is well-known that papillary thyroid carcinomas can occur secondary to ionizing radiation exposure, particularly in children.^6,53,77 After the Chernobyl nuclear reactor accident in 1986, the incidence of thyroid carcinomas in children in affected areas of Belarus increased from less than 1 per million to more than 90 per million.¹⁰ The primary known molecular mechanism of radiation-induced papillary carcinoma development is through the Ret/PTC group of oncogenes. Ret proto-oncogene is a receptor tyrosine kinase normally involved in the glial-derived neurotropic factor-signaling pathway in neuroendocrine and neural cells. In thyroid follicular cells, the alignment of chromosomes during interphase places the ret proto-oncogene in close proximity to several other constitutively expressed genes with which it can recombine during repair of ionizing radiation–induced double-stranded DNA breaks.^53,55 These Ret/PTC rearrangements allow for unregulated expression of chimeric oncoproteins with constitutive tyrosine kinase activity. Ret/PTC expression is found in roughly one third of all papillary carcinomas, but in the majority of all radiation-induced papillary carcinomas.³⁹ While Ret/PTC1-expressing papillary carcinomas are often well differentiated, Ret/PTC3 expression is associated with a solid phenotype and a more aggressive clinical course.^53,90

Sporadic papillary thyroid carcinomas unrelated to radiation exposure make up more than two thirds of all cases, and several genetic events have been identified as important in their tumorigenesis.⁵⁴ A form of the B-type Raf kinase, or BRAF, with a point mutation resulting in V600E has been identified in approximately 45% of sporadic papillary carcinomas, particularly the tall-cell variant.⁹² BRAF expression has been associated with dedifferentiation and disease progression. NTRK1 is a receptor tyrosine kinase normally involved in nerve growth factor signaling.⁸³ Like Ret/PTC rearrangements, NTRK1 can recombine with the 5' end of other heterologous genes and form a constitutively active oncogene, such as TRK-T1, leading to papillary carcinomas. However, NTRK1 rearrangements are less frequent than Ret/PTC rearrangements and are not associated with radiation exposure. Finally, chromosomal rearrangement of the PTEN tumor-suppressor gene leading to its loss of function has been recently associated with papillary carcinoma formation.⁶⁰

Ras mutations have been implicated in the development of follicular thyroid carcinomas, particularly N-ras activating mutations at codon 61.^54,86,89 Expression of a Pax8-PPAR fusion protein has been detected in a small number of follicular carcinomas and follicular variants of papillary carcinomas.^42,43 While controversy exists over the ability of chronic thyroid stimulating hormone (TSH) stimulation to result in thyroid tumorigenesis, follicular carcinomas are most prevalent in iodine-deficient regions, suggesting that TSH stimulation may play a role.^24,45,68,89 An elevation in the risk of thyroid tumorigenesis in patients with certain types of goiter has been reported,^24,50,67,85 although there is a lack of consensus regarding this association.

Loss of p53 function is the primary genetic alteration identified in the development of anaplastic thyroid carcinomas,^30,54,63 although BRAF and Ret/PTC3 mutations have been associated with some degree of anaplasia in papillary carcinomas.^54,92 ß-catenin activating mutations have also been detected in anaplastic thyroid carcinomas, where the protein likely mediates loss of cell-cell adhesions and also acts as a transcription factor in upregulating growth-promoting genes.²⁵

	Genetic Events in Thyroid Tumors of C Cell Origin

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Medullary thyroid carcinomas, or C-cell carcinomas, arise from the calcitonin-secreting parafollicular C cells of the thyroid gland. These tumors can occur as part of an inherited syndrome, such as MEN type 2A or type 2B or familial medullary thyroid carcinoma, which together account for 20%–25% of all medullary thyroid carcinomas.^17,61,77 The ret proto-oncogene, which can undergo rearrangements in papillary carcinoma as previously described, is also important in initiating medullary carcinoma. In medullary carcinoma, the full-length ret proto-oncogene has gain-of-function point mutations involving 1 of several possible codons.^19,52,61 As a result, Ret is constitutively active in the neuroendocrine tissues normally expressing this protein, such as thyroid C cells and neuroendocrine cells of the adrenal medulla. All of the known hereditary forms of medullary carcinoma are autosomal-dominant and involve ret mutations. While sporadic medullary carcinomas comprise more than 75% of cases, little is known about specific genetic mutations initiating this form of thyroid cancer. However, somatic ret point mutations have been identified in up to 50% of sporadic cases.²⁷

	Animal Models of Thyroid Cancer

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Thyroid cancer arises as a spontaneous disease in domestic animal species, particularly follicular adenomas in cats, solid-to-follicular carcinomas in dogs, and C-cell (ultimobranchial) carcinomas in bulls.^5,9,64 However, the incidence of tumorigenesis in these species is too low for feasible use as experimental models of the human disease, and the genotypic similarities to the human disease remain unclear.

Many xenobiotics result in thyroid tumors of follicular cell origin in laboratory mice and rats, generally by lowering thyroxine (T4) levels, leading to an increase in circulating TSH and thyroid follicular cell proliferation.⁹ Some of the implicated compounds include hepatic Cyp2B inducers, thyroperoxidase and 5'-deiodinase inhibitors, and inhibitors of the sodium/iodide symporter.⁸ This pathway of thyroid tumorigenesis is believed to be much less important in humans than in rodents, as the half-life of thyroid hormones is 5–18 times greater in humans than in rodents because of the presence of the transport protein thyroxine-binding globulin in circulation.⁸ Thus, the shorter half-life of thyroid hormones in rodents results in greater ease of disruption of thyroid hormone homeostasis. In the B6C3F₁ laboratory mouse strain, which is commonly used in long-term toxicity studies, thyroid tumorigenesis occurs in 1%–10% of females and 0.8% of males by age 24 months (Charles River Laboratories, www.criver.com). However, the incidence rate and distribution of tumor types make these spontaneous models insufficient for use in mechanistic studies of thyroid cancer.

The majority of published studies utilizing mouse models of thyroid cancer have involved xenografts of human thyroid tumor tissue or immortalized thyroid carcinoma cell lines into severe combined immunodeficient (SCID) mice. SCID mouse tumor xenograft models have several drawbacks, including tumor implantation into an artificial microenvironment, rare success of metastasis from a subcutaneous location, lack of normal B- and T-cell function for evaluation of immune components of disease, and frequent onset of multiple spontaneous neoplasms.² Attempts to address these drawbacks in thyroid models have included orthotopic implantation of a thyroid carcinoma cell line into the mouse thyroid gland,^20,37 selection of an anaplastic thyroid carcinoma cell line for pulmonary metastatic ability by serially passaging through nude mice,⁹⁷ and implantation of human peripheral blood lymphocytes into a SCID mouse model of thyroid carcinoma to confer partial immune competence.²⁸ The most commonly used cell lines in SCID mouse models of thyroid cancer include papillary thyroid carcinoma cell lines and NPA;^16,56 follicular thyroid carcinoma cell lines FTC-133, FTC-238, RTC-R2 and FRO;^26,74,79,84 anaplastic thyroid carcinoma cell lines ARO, DRO, WRO, KAT-4, and Thena;^{3,11,20,31,32,57,72,78,87,88,94,95,97} and medullary thyroid carcinoma cell lines TT and rMTC.^{4,21,41,51,62,80,81,93}

	Genetically Engineered Mouse Models of Thyroid Cancer

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Genetically engineered mouse models of thyroid cancer facilitate analysis of the roles of specific genetic mutations in thyroid tumorigenesis. Because thyroid cancer truly encompasses several diseases with different etiologies and relevant genetic mutations, no single transgenic mouse model of thyroid cancer can fully recapitulate the full spectrum of disease. However, several models have successfully reproduced various aspects and have offered insight into genetic mutations underlying thyroid tumorigenesis. These mouse models of thyroid cancer offer examples of positive genotype-phenotype correlation.

Over the past decade, several genetically engineered mouse models of thyroid cancer have been utilized to replicate variants of the human disease (Tables 1, 2). In most cases, transgenic mice have been produced using the highly active bovine thyroglobulin (Tg) promoter to specifically target transgene expression to thyroid follicular cells or using the human or rat calcitonin/calcitonin gene-related peptide (CGRP) promoter to target transgene expression to C cells. In some cases, tumor suppressor gene knockout mice have been created and cross-bred with transgenic mice expressing thyroid-specific oncogenes, resulting in increased tumorigenesis and/or an aggressive phenotype.

	Mouse Models of Papillary Thyroid Carcinoma

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

FVB/N strain transgenic mice expressing thyroid-targeted Ret/PTC1 tyrosine kinase consistently developed bilateral papillary thyroid carcinomas with similar histopathologic features to the human disease, including papillary folds, ground-glass nuclei, and nuclear invaginations (Figs. 1–3).³³ Tumorigenesis was abolished when all 3 critical phosphotyrosine residues involved in signaling pathways mediated by Ret/PTC1 were mutated, but not when single residues were mutated, although tumor incidence was decreased.⁷ Thus, signaling pathways mediated by each single phosphotyrosine residue were not solely essential for tumor development, but all 3 worked in concert to induce tumorigenesis. Like the human disease, these tumors accumulated less radioactive iodide than did normal thyroid tissue. The severity of disease varied markedly between high- and low-copy founder lines. High-copy lines had dysplastic thyroid glands at birth and developed carcinomas as young as 4 days of age, as compared with 1–6 months of age in the low-copy line.^13,71

View larger version (135K): [in this window] [in a new window]   Fig. 1 Thyroid gland; Ret/PTC1 transgenic mouse. Well-demarcated bilateral papillary thyroid carcinomas are present. Remaining non-neoplastic thyroid gland has large, quiescent follicles due to dietary L-thyroxine supplementation. HE; Bar = 1 mm. Tissue courtesy of Dr. Je-Yoel Cho. Fig. 2. Thyroid gland; Ret/PTC1 transgenic mouse. Higher magnification of a well-differentiated papillary thyroid carcinoma, illustrating the fronds of neoplastic cells extending into colloid-filled follicles. HE; Bar = 50 µm. Tissue courtesy of Dr. Je-Yoel Cho. Fig. 3. Thyroid gland; Ret/PTC1 transgenic mouse. High-magnification thin section of a papillary thyroid carcinoma demonstrating the nuclear invaginations (arrowheads) and ground-glass nuclei (inset) that are characteristic of the human tumor. HE; Bar = 15 µm (inset: bar = 3 µm). Photo reproduced from Jhiang et al: Endocrinology 137:375–378, 1996, with permission from The Endocrine Society. Fig. 4. Thyroid gland; Ret/PTC1 transgenic x p53–/– mouse. Bilateral papillary thyroid carcinomas of large size have replaced all normal thyroid tissue and invaded the adjacent trachea. HE; Bar = 1 mm. Photo reprinted from La Perle et al: Am J Pathol 157:671–677, 2000, with permission from the American Society for Investigative Pathology. Fig. 5. Thyroid gland; Ret/PTC1 transgenic x p53–/– mouse. Higher magnification of a poorly differentiated papillary thyroid carcinoma with multiple mitotic figures. HE; Bar = 50 µm. Photo reprinted from La Perle et al: Am J Pathol 157:671–677, 2000, with permission from the American Society for Investigative Pathology. Fig. 6. Liver; Ret/PTC1 transgenic x p53–/– mouse. Two metastatic papillary thyroid carcinomas are present within the hepatic parenchyma (lower). HE; Bar = 1 mm. Positive immunostaining for thyroglobulin confirms the lesions as metastatic papillary thyroid carcinomas (inset). Chromagen DAB detection method with HE. Bar = 50 µm. Photo reprinted from La Perle et al: Am J Pathol 157:671–677, 2000, with permission from the American Society for Investigative Pathology. Fig. 7. Thyroid gland; TRßPV/– mouse. A follicular thyroid carcinoma invades the thyroid capsule (arrow). HE; Bar = 50 µm. Photo reproduced from Kato et al: Endocrinology 145:4430–4438, 2004, with permission from the The Endocrine Society (courtesy of Dr. Sheue-yann Cheng). Fig. 8. Thyroid gland; TRßPV/– mouse. Vascular invasion is characteristic of follicular thyroid carcinomas (arrow). HE; Bar = 50 µm. Photo reproduced from Kato et al: Endocrinology 145:4430–4438, 2004, with permission from The Endocrine Society (courtesy of Dr. Sheue-yann Cheng). Fig. 9. Thyroid gland; TRßPV/– mouse. Foci of anaplasia are noted in regions of follicular hyperplasia and carcinoma (arrow). HE; Bar = 50 µm. Photo reproduced from Kato et al: Endocrinology 145:4430–4438, 2004, with permission from The Endocrine Society (courtesy of Dr. Sheue-yann Cheng). Fig. 10. Thyroid gland; CGRP-RetC634R transgenic mouse. A large, invasive C-cell carcinoma is present within the right lobe of the thyroid gland (arrow), while the opposite lobe contains a papillary thyroid carcinoma. HE; Bar = 1 mm. Photo reprinted from Reynolds et al: Oncogene 20:3986–3994; 2001, with permission from Nature Publishing Group (courtesy of Dr. Aaron Cranston and Professor Bruce Ponder). Fig. 11. Thyroid gland; CGRP-RetC634R transgenic mouse. Higher magnification of a C-cell carcinoma reveals characteristic neuroendocrine packeting of neoplastic cells. Calcitonin immunostain with hematoxylin counterstain; Bar = 500 µm. Photo reprinted from Reynolds et al: Oncogene 20:3986–3994; 2001, with permission from Nature Publishing Group (courtesy of Dr. Aaron Cranston and Professor Bruce Ponder). Fig. 12. Thyroid gland; CGRP-RetC634R transgenic mouse. High magnification of a C-cell carcinoma demonstrates the fine fibrovascular stroma dividing lobules of polyhedral neoplastic cells. Ret immunostain with hematoxylin counterstain; Bar = 30 µm. Photo reprinted from Reynolds et al: Oncogene 20:3986–3994; 2001, with permission from Nature Publishing Group (courtesy of Dr. Aaron Cranston and Professor Bruce Ponder).

Tg-Ret/PTC3

Thyroid-targeted Ret/PTC3 tyrosine kinase expression led to the follicular cell hyperplasia and development of a solid variant of papillary thyroid carcinoma in almost all C3H/He strain transgenic mice by the age of 6 months.⁵⁸ Metastases to cervical lymph nodes did occur in this model, albeit rarely (less than 10%). Ret/PTC3–induced thyroid tumors did not dedifferentiate into the more aggressive phenotype often seen in human patients with Ret/PTC3 chromosomal rearrangements. Cross-breeding Tg-Ret/PTC3 transgenic mice with p53^–/– mice resulted in earlier onset of tumorigenesis, with microcarcinoma formation by the age of 3 months and the development of primary tumors up to 285 times the mass of wild-type mouse thyroid glands.⁵⁹ However, metastases were still rare in the p53^–/– crosses, and progression did not occur to an anaplastic phenotype.

Tg-BRAF^V600E

Transgenic mice of the FVB/N strain with thyroid targeted BRAF^V600E serine/threonine kinase expression developed multifocal bilateral papillary thyroid carcinomas between the ages of 12 and 22 weeks.^40,92 Features of the human tall cell variant, which is characterized by tall columnar cells with intensely eosinophilic cytoplasm,¹⁷ were present in approximately half of the tumors. Foci of anaplasia were noted arising within and adjacent to well-differentiated papillary tumors, although there was no evidence of the necrosis commonly seen in human anaplastic carcinomas. In a high-expression transgenic line, tumors frequently invaded the surrounding fibrovascular tissue, sometimes leading to tracheal compression, but did not metastasize. Similar to the high-copy Tg-Ret/PTC1 mice, high-expression Tg-BRAF mice developed thyroid hormone derangements at a young age. However, in contrast to the Tg-Ret/PTC1 model, Tg-BRAF mice remained euthyroid and developed large goiters as a compensatory response to the high circulating TSH levels.

Tg-TRK-T1

More than 50% of transgenic mice of the B6C3F1 strain with thyroid-targeted TRK-T1 tyrosine kinase expression developed follicular cell hyperplasia, which often progressed to papillary thyroid carcinomas in animals over 7 months of age.⁷⁰ While tumors were composed of the papillae found in the human tumor, they lacked the classic nuclear clearing typical of papillary carcinomas. Few thyroid tumors in TRK-T1 mice developed the less-differentiated solid regions, and none of the tumors metastasized. It is likely that while TRK-T1 predisposed mice to develop papillary thyroid carcinomas, additional genetic mutations were required for transformation based upon the variability of tumor formation even within the same founder line.

Tg-c-Ha-ras

Transgenic mice expressing thyroid-targeted c-Ha-ras had a predisposition to developing papillary thyroid carcinomas.^23,69 Two founder mice developed the disease at 10–12 months of age but did not transmit the transgene to offspring. A third founder mouse and 90% of progeny developed follicular cell hyperplasia, but not neoplasia. The fourth founder, which carried 20–30 copies of the ras transgene, developed papillary thyroid carcinoma with lung metastases at 9 months of age, although a thyroid origin of the lung tumors was not definitively established. When this founder, a C57BL/6J.DBA/2J strain, was backcrossed with DBA2J mice, all of the offspring had thyroid dysgenesis and early lethality. Backcrossing with C57BL/6J mice resulted in a normal phenotype. Thus, while the founder mice demonstrated papillary thyroid carcinomas, this phenotype could not be maintained in further generations.

Other models

Tumors with pathologic features of papillary thyroid carcinoma have been described in transgenic mice expressing thyroid-targeted human papillomavirus type 16 E7 oncogene, which inhibits retinoblastoma (Rb) function,⁴⁷ or the adenosine A2ß receptor, which stimulates cAMP signaling.^14,15,48 Coexpression of both transgenes enhanced tumorigenesis. In a mouse model of Carney complex tumor syndrome, a disease involving multiple endocrine and non-endocrine neoplasms, heterozygous knockout of the R1A regulatory subunit of protein kinase A led to papillary thyroid carcinoma development in 5 out of 44 mice.³⁸

	Mouse Models of Follicular Thyroid Carcinoma

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
TRß^PV/PV

A genetically engineered mouse model of follicular thyroid carcinoma was created by introduction of a dominant-negative mutation, named PV for the patient first identified with the mutation, into the thyroid hormone receptor ß (TRß) locus by homologous recombination in a 129/Sv x C57BL/6J background strain.³⁵ The PV mutation results in loss of TRß binding ability to active T3 hormone, abolishing transcriptional activation. The lack of negative feedback by T3 on the hypothalamus and pituitary gland led to persistent upregulation of TSH and follicular cell hyperplasia in these mice, which often caused dyspnea due to tracheal compression.⁸² TRß^PV/PV homozygotes developed follicular cell hyperplasia by 3 weeks of age and invasive follicular thyroid carcinomas by 4–5 months of age. Hematogenous metastases to the lungs and heart were noted in the majority of mice over 5 months of age, and the metastases often had foci of anaplasia consisting of spindle-shaped cells. A similar phenotype was evident when TRß^PV/– mice were created by cross-breeding TRß^PV/PV mice with TRß knockout mice (Figs. 7–9).³⁶ While this mouse model offers a reasonably good recapitulation of human follicular carcinoma arising from hyperplastic goiter, it differs in that these mice have elevated circulating T3 and T4 levels due to production by the tumor cells, while human follicular thyroid carcinomas are infrequently functional.¹⁷

Tg-Rap1b^G12V

Transgenic mice overexpressing a constitutively active form of Rap1 that lacks GTPase activity, Rap1b^G12V, developed follicular cell hyperplasia and adenomas within 6 months of goitrogen (methimazole and perchlorate) treatment and follicular carcinomas after 1 year.⁶⁶ Hyperplasia and adenomas were reversible upon 2 months of goitrogen removal provided that progression to carcinoma was absent, indicating that the early adenomas were not truly autonomous. While follicular carcinomas were locally invasive into the thyroid capsule, local blood vessels and perithyroidal soft-tissue metastases were not detected. The constitutively active Rap1b^G12V cassette used to create this mouse model was floxed and followed by a dominant negative Rap1b^S17N such that upon cross-breeding with a tamoxifen-inducible Cre mouse and administration of tamoxifen, the constitutively active Rap1b^G12V was removed and the dominant negative Rap1b^S17N was expressed in its place. When the Rap1b "switch" was made from constitutively active Rap1b^G12V to dominant negative Rap1b^S17N, thyroid gland size was reduced by 50% in the face of continued goitrogen treatment. Ki67, BrdU, and PCNA labeling indices and terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling indicated that decreased cellular proliferation, rather than increased apoptosis, accounted for the decrease in thyroid hyperplasia. This study suggests an important role for Rap1b in TSH-induced thyroid hyperplasia and tumorigenesis.

Other models

Follicular thyroid carcinomas have been described in mice expressing a mutated form of the 1B adrenergic receptor under the control of the Tg promoter, which leads to upregulated cAMP and IP3-Ca⁺⁺ signaling in the thyroid gland.^15,48,49 Tg-ki-ras transgenic mice also developed well-differentiated follicular thyroid carcinomas at a low rate with long latency upon treatment with TSH or goitrogens, suggesting that while ras mutation alone is not sufficient to induce follicular thyroid carcinomas, it acts as a predisposing factor.¹²

	Mouse Models of Anaplastic Thyroid Carcinoma

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Tg-SV40 LT

Anaplastic thyroid carcinomas developed in transgenic mice expressing thyroid-targeted Simian virus 40 large T antigen on a C57B/6J x DBA/2J background, which is the only published transgenic mouse model of this type of thyroid cancer.⁴⁶ Mice were profoundly hypothyroid and required T4 supplementation in order to survive to an age where they could reproduce. By the age of 4–6 weeks and as early as 9 days of age, most mice developed solid, anaplastic carcinomas with hemorrhage, necrosis, and few, if any, residual thyroid follicles. A few mice survived long enough to develop lung metastases, while invasion of the trachea led to dyspnea and death in 90% of the transgenic mice by 22 weeks of age.

	Mouse Models of Medullary Thyroid Carcinoma

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
CGRP-Ret^C634R

It is well known that in humans, point mutation of the ret proto-oncogene can lead to constitutive activation in neuroendocrine cells, such as thyroid C cells, leading to medullary thyroid carcinoma and/or the MEN syndromes. In transgenic mice expressing Ret with the common MEN 2A point mutation C634R under the control of the C cell–specific CGRP promoter, nearly all of the transgenic mice in all 3 founder lines developed early C cell hyperplasia with progression to bilateral medullary thyroid carcinomas by 8–12 months of age and rare systemic metastases (Figs. 10–12).⁵² Circulating calcitonin levels were elevated, indicating that these tumors were functional. Overexpression of wild-type Ret did not result in C-cell tumorigenesis.⁶⁶ In one study, mice from a single CGRP-Ret^C634R founder line surprisingly developed papillary carcinomas, which were interpreted as evidence that activated Ret can transform thyroid follicular cells in addition to C cells.⁶⁵ The development of papillary carcinoma is likely an artifact of transgene leakiness in follicular cells due to the specific chromosomal integration site in this founder line, since the CGRP promoter should target transgene expression to neuroendocrine and neural cells. There was marked variation in tumor penetrance between mouse background strains in a study using the CGRP-Ret^C634R model of medullary carcinoma, with tumors in 0% of FVB/N mice, 14% of BALB/c mice, 64% of C67BL/6J mice, and 98% of CBA/ca mice all backcrossed from a single transgenic founder.¹⁹ Tumor size positively correlated with the degree of penetrance. This study highlights the role of modifier genes in disease phenotype and the need for careful consideration during selection of mouse background strains in a study, particularly when the resultant phenotype is unexpected.

Rb and p53 deletional mutation

Approximately 40% of mice with simultaneous heterozygous deletional mutation of Rb and p53 (Rb^+/– x p53^+/–) on a 129 strain background developed C-cell hyperplasia and medullary thyroid carcinomas at approximately 7 months of age.²⁹ Tumors were generally well differentiated and nonmetastatic. Interestingly, in one recent study using an Rb^+/– model with normal p53 status on a 129/Sv x C57BL/6 background, 56% of mice developed medullary thyroid carcinomas, and there were rare metastases to liver, lung, lymph node, and adrenal gland.⁹⁶ Thus, loss of 1 allele of Rb was sufficient to predispose mice to medullary thyroid carcinomas, depending on the background strain. Naturally, Rb^+/– and p53^+/– mice also developed many nonthyroidal neoplasms and had shortened life spans. Spontaneous activating mutations of Ret were detected in 4 out of 8 medullary thyroid carcinomas from Rb^+/– x p53^+/– mice.¹⁸ While Rb loss has been detected immunohistochemically in human thyroid malignancies of many types,¹ its precise role is unclear in the development of spontaneous medullary thyroid carcinoma in humans.

CGRP-v-Ha-ras

Transgenic mice of a C57BL/6 x SJL strain expressing v-Ha-ras in C cells under control of the CGRP promoter developed C-cell hyperplasia progressing to medullary thyroid carcinoma in 85%–93% of animals (depending on founder line) between the ages of 6–12 months.³⁴ Tumors were functional in secreting calcitonin, as is common in the human disease. Metastasis occurred rarely to the lungs and cervical lymph nodes. Some tumors had amyloid deposition, cystic cavitation, and vascular invasion and hemorrhage, characteristic features of human medullary thyroid carcinomas. Ras mutations have not been detected in human cases of medullary thyroid carcinoma. Thus, this mouse model offers a better phenotypic than genotypic representation of the human disease.

Other models

All transgenic mice coexpressing a truncated form of the polyomavirus (Py) middle-T antigen and the full-length Py small-T antigen under control of a composed Py early promoter/enhancer developed medullary thyroid carcinomas by 3–7 months of age.²² Tumors did not metastasize, and the animals had an unexpected waviness of hair and whiskers due to disorganized hair follicles in the dermal layer. In one of the earliest mouse models of medullary carcinomas, transgenic mice carrying the c-mos proto-oncogene, under control of the Moloney murine sarcoma virus long-terminal repeat, developed a syndrome similar to MEN 2A, consisting of medullary carcinomas and adrenal medullary pheochromocytomas, after a long latency.⁷⁵ In this model, like the CGRP-Ret^C634R model,¹⁹ tumors were more prevalent on a BALB/c background than an FVB/N background.

	The Future of Thyroid Cancer Research Using Genetically Engineered Mouse Models

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
Transgenic mice expressing Ret/PTC1, Ret/PTC3 Trk-T1, BRAF, or ras offer a reasonable approximation of the features of papillary thyroid carcinomas in humans. However, even with a p53 knockout, no model has been able to demonstrate significant tumor dedifferentiation or metastasis. One limitation has been the fact that p53 knockout mice develop extrathyroidal neoplasms at a high rate, resulting in a shortened life span. A tissue-specific p53 knockout would help to eliminate this problem and allow the mice to live long enough to potentially develop more advanced thyroid cancer.

Follicular thyroid carcinoma has been primarily investigated using a single mouse model, TRß^PV/PV. The limitation of this model is the presence of hyperthyroidism and thyroid hormone resistance, which is not typical of the human disease. Because follicular thyroid carcinomas are more common in areas of dietary iodide deficiency, it is interesting that chronic TSH stimulation in the TRß^PV/PV mice resulted in this type of neoplasm. However, rodents are notoriously susceptible to thyroid neoplasia because of perturbations of the pituitary-thyroid axis.^8,9

There currently is a paucity of genetically engineered mouse models of anaplastic thyroid carcinoma, although in mice, SCID xenograft models are abundant. As previously mentioned, few papillary and follicular thyroid carcinomas undergo significant dedifferentiation in transgenic mouse models. The only published transgenic model of anaplastic carcinoma, Tg-SV40 LT, rapidly developed severe hypothyroidism and fatal thyroid tumors as a result of tracheal invasion. An inducible model would facilitate maintenance and breeding of these mice and would better reproduce anaplastic carcinoma in the adult animal, which is more typical in human disease.

Many of the mouse models of thyroid follicular cell neoplasia fail to reproduce the normal hormonal milieu present in humans with thyroid cancer. For example, derangement of thyroid function in mouse models remains a problem. Rapid onset of dysplasia or neoplasia replacing the majority of the normal thyroid tissue, especially in neonatal and juvenile mice, often results in significant hypothyroidism unless thyroid hormone supplementation is instituted. In addition, human thyroid neoplasms are more than twofold more common in women than in men, suggesting that estrogen plays a role in tumorigenesis, while no sex predilection has been achieved in the current mouse models.

Reproduction of the MEN 2A syndrome using CGRP-Ret^C634R has been quite successful. However, in this model, as well as the Rb^+/– models, there appears to be a significant contribution of background strain to the development of medullary thyroid carcinomas. In addition, these models develop several extrathyroidal neoplasms common to the MEN 2A syndrome, while only the CGRP-v-Ha-ras model mimics the presence of medullary thyroid carcinoma alone, which is the most common form of the disease in humans.

Overall, there is a need for the development of inducible mouse models of thyroid cancer. All of the available mouse models have genetic mutations from the earliest stages of development onward, while many naturally occurring human cases of thyroid cancer result from somatic mutations during childhood or beyond. Additionally, little research has been performed to test novel therapies in vivo. For example, while a great deal of recent research has focused upon signal transduction inhibitors directed toward Ret, ras, raf, and ERK in tumors of follicular and C-cell origin in vitro,⁹¹ these compounds have only been tested in a few SCID mouse xenograft models of thyroid cancer. Pharmacologic therapeutic intervention using genetically engineered mouse models of thyroid cancer would provide more useful information as to the feasibility, efficacy, and safety of signal transduction inhibitors in a relatively realistic in vivo setting. The continually increasing incidence of thyroid cancer in humans and lack of successful treatment options for dedifferentiated, invasive, or metastatic lesions makes mouse models invaluable in future therapeutic investigations.

	Acknowledgement

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 
We would like to thank Tim Vojt in the Ohio State University College of Veterinary Medicine for technical assistance with figure preparation. This work was generously supported by Schering-Plough Research Institute.

	References

Top Abstract Genetic Events in Thyroid... Genetic Events in Thyroid... Animal Models of Thyroid... Genetically Engineered Mouse... Mouse Models of Papillary... Mouse Models of Follicular... Mouse Models of Anaplastic... Mouse Models of Medullary... The Future of Thyroid... Acknowledgement References

 

1. Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP. Retinoblastoma expression in thyroid neoplasms. Mod Pathol 13:562–569, 2000[CrossRef][ISI][Medline]
2. Bankert RB, Hess SD, Egilmez NK. SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci 7:c44–62, 2002[Medline]
3. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953–961, 2002[CrossRef][ISI][Medline]
4. Behe M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 46:1012–1015, 2005[Abstract/Free Full Text]
5. Black HE, Capen CC, Young DM. Ultimobranchial thyroid neoplasms in bulls: a syndrome resembling medullary thyroid carcinoma in man. Cancer 32:865–878, 1973[CrossRef][ISI][Medline]
6. Boice JD. Radiation-induced thyroid cancer: what's new?. J Natl Cancer Inst 97:703–705, 2005[Free Full Text]
7. Buckwalter TLF, Venkateswaran A, Lavender M, La Perle KMD, Cho J-Y, Robinson ML, Jhiang SM. The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 21: 8166–8172, 2002[CrossRef][ISI][Medline]
8. Capen CC. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol 25:39–48, 1997[Abstract/Free Full Text]
9. Capen CC. Overview of structural and functional lesions in endocrine organs in animals. Toxicol Pathol 29:8–33, 2001[CrossRef][ISI][Medline]
10. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97:724–732, 2005[Abstract/Free Full Text]
11. Chang JW, Yeh KY, Shen YC, Hsieh JJ, Chuang CK, Liao SK, Tsai LH, Wang CH. Production of multiple cytokines and induction of cachexia in athymic nude mice by a new anaplastic thyroid carcinoma cell line. J Endocrinol 179:387–394, 2003[Abstract]
12. Chiappetta G, Fabien N, Picone A, Califano D, Monaco C, de Franciscis V, Vecchio G, Santelli G. Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization. Oncol Res 8:85–93, 1996[ISI][Medline]
13. Cho J-Y, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. Early cellular abnormalities induced by Ret/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 18:3659–3665, 1999[CrossRef][ISI][Medline]
14. Coppée F, Depoortere F, Bartek J, Ledent C, Parmentier M, Dumont JE. Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumors. Oncogene 17:631–41, 1998[CrossRef][ISI][Medline]
15. Coppée F, Gérard A-C, Denef J-F, Ledent C, Vassart G, Dumont JE, Parmentier M. Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. Oncogene 13:1471–1482, 1996[ISI][Medline]
16. Corsetti F, Chianelli M, Cornelissen B, Van de Wiele C, D'Alessandria C, Slegers G, Mather SJ, Di Mario U, Filetti S, Scopinaro F, Signore A. Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. Cancer Biother Radiopharm 19: 57–63, 2004[CrossRef][ISI][Medline]
17. Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease, 6th ed., pp. 1142–1147. W. B. Saunders Company, Philadelphia, PA, USA, 1999.
18. Coxon AB, Ward JM, Geradts J, Otterson GA, Zajac-Kaye M, Kaye FJ. RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 17:1625–1628, 1998[CrossRef][ISI][Medline]
19. Cranston AN, Ponder BAJ. Modulation of medullary thyroid carcinoma penetrance suggests the presence of modifier genes in a RET transgenic mouse model. Cancer Res 63:4777–4780, 2003[Abstract/Free Full Text]
20. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 145:5840–5846, 2004[Abstract/Free Full Text]
21. Ezzat S, Huang P, Dackiw A, Asa SL. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11:1336–1341, 2005[Abstract/Free Full Text]
22. Felici A, Giorgio M, Krauzewicz N, Della Rocca C, Santoro M, Rovere P, Manni I, Amati P, Pozzi L. Medullary thyroid carcinomas in transgenic mice expressing a Polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens. Oncogene 18:2387–2395, 1999[CrossRef][ISI][Medline]
23. Feunteun J, Michiels F, Rochefort P, Caillou B, Talbot M, Fournes B, Mercken L, Schlumberger M, Monier R. Targeted oncogenesis in the thyroid of transgenic mice. Horm Res 47:137–139, 1997[ISI][Medline]
24. Gandolfi PP, Frisina A, Raffa M, Renda F, Rocchetti O, Ruggeri C, Tombolini A. The incidence of thyroid carcinoma in multinodular goiter: retrospective analysis. Acta Biomed Ateneo Parmense 75:114–117, 2004[Medline]
25. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 59:1811–1815, 1999[Abstract/Free Full Text]
26. Gerling MC, Jossart G, Duh QY, Weier HU, Clark OH, Young DM. Invasion of human follicular thyroid carcinoma cells in an in vivo invasion model. Thyroid 9:1221–1226, 1999[ISI][Medline]
27. Gimm O, Dralle H. C-cell cancer-prevention and treatment. Langenbecks Arch Surg 384:16–23, 1999[CrossRef][ISI][Medline]
28. Gyory F, Mezosi E, Szakall S, Bajnok L, Varga E, Borbely A, Gazdag A, Juhasz I, Lukacs G, Nagy EV. Establishment of the hu-PBL-SCID mouse model for the investigation of thyroid cancer. Exp Clin Endocrinol Diabetes 113:359–364, 2005[CrossRef][ISI][Medline]
29. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55:1146–1151, 1995[Abstract/Free Full Text]
30. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, Asa SL. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol 8:21–28, 1997[ISI][Medline]
31. Iuliano R, Trapasso F, Le Pera I, Schepis F, Sama I, Clodomiro A, Dumon KR, Santoro M, Chiariotti L, Viglietto G, Fusco A. An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res 63:882–886, 2003[Abstract/Free Full Text]
32. Jacobson A, Salnikov A, Lammerts E, Roswall P, Sundberg C, Heldin P, Rubin K, Heldin NE. Hyaluronan content in experimental carcinoma is not correlated to interstitial fluid pressure. Biochem Biophys Res Commun 305:1017–1023, 2003[CrossRef][ISI][Medline]
33. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho J-Y, Xing S, Ledent C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375–378, 1996[Abstract]
34. Johnston D, Hatzis D, Sunday ME. Expression of v-Ha-ras driven by the calcitonin/calcitonin gene-related peptide promoter: a novel transgenic murine model for medullary thyroid carcinoma. Oncogene 16:167–177, 1998[CrossRef][ISI][Medline]
35. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA, Kazlauskaite R, Pankratz DG, Wynshaw-Boris A, Refetoff S, Weintraub B, Willingham MC, Barlow C, Cheng S. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97:13209–13214, 2000[Abstract/Free Full Text]
36. Kato Y, Ying H, Willingham MC, Cheng S-Y. A tumor-suppressor role for thyroid hormone ß receptor in a mouse model of thyroid carcinogenesis. Endocrinology 145:4430–4438, 2004[Abstract/Free Full Text]
37. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN, Myers JN. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 11:1713–1721, 2005[Abstract/Free Full Text]
38. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH, Carney JA, Westphal H, Stratakis CA. A mouse model of the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 65:4506–4514, 2005[Abstract/Free Full Text]
39. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 11:2459–2467, 1995[ISI][Medline]
40. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao X-H, Refetoff S, Nikiforov YE, Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238–4245, 2005[Abstract/Free Full Text]
41. Kraeber-Bodere F, Sai-Maurel C, Campion L, Faivre-Chauvet A, Mirallie E, Cherel M, Supiot S, Barbet J, Chatal JF, Thedrez P. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 1:267–274, 2002[Abstract/Free Full Text]
42. Kroll TG. Molecular events in follicular thyroid tumors. Cancer Treat Res 122:85–105, 2004[Medline]
43. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM. Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223–231, 2005[Abstract/Free Full Text]
44. LaPerle KMD, Jhiang SM, Capen CC. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am J Pathol 157:671–677, 2000[Abstract/Free Full Text]
45. Lawal O, Agbakwuru A, Olayinka OS, Adelusola K. Thyroid malignancy in endemic nodular goitres: prevalence, pattern and treatment. Eur J Surg Oncol 27:157–61, 2001[CrossRef][ISI][Medline]
46. Ledent C, Coppee F, Dumont JE, Vassart G, Parmentier M. Transgenic models for proliferative and hyperfunctional thyroid diseases. Exp Clin Endocrinol Diabetes 104 Suppl 3:43–46, 1996
47. Ledent C, Dumont J, Vassart G, Parmentier M. Thyroid adenocarcinomas secondary to tissue-specific expression of simian virus-40 large T antigen in transgenic mice. Endocrinology 129:1391–1401, 1991[Abstract/Free Full Text]
48. Ledent C, Franc B, Parmentier M. Transgenic mouse models: their interest in thyroid tumors. Arch Anat Cytol Pathol 46:31–37, 1998[Medline]
49. Ledent C, Marcotte A, Dumont JE, Vassart G, Parmentier M. Differentiated carcinomas develop as a consequence of the thyroid-specific expression of a thyroglobulin-human papillomavirus type 16 E7 transgene. Oncogene 10:1789–1797, 1995[ISI][Medline]
50. Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 8:991–997, 1999[Abstract/Free Full Text]
51. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB, Nelkin BD. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96:4540–4545, 1999[Abstract/Free Full Text]
52. Michiels F-M, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94:3330–3334, 1997[Abstract/Free Full Text]
53. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3–16, 2002[CrossRef][ISI][Medline]
54. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15:319–328, 2004[CrossRef][ISI][Medline]
55. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290:138–41, 2000[Abstract/Free Full Text]
56. Okano K, Usa T, Ohtsuru A, Tsukazaki T, Miyazaki Y, Yonekura A, Namba H, Shindoh H, Yamashita S. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth. Endocr J 46:243–252, 1999[ISI][Medline]
57. Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:5027–5032, 2003[Abstract/Free Full Text]
58. Powell DJ, Russell J, Nibu K, Li G, Rhee E, Liao M, Goldstein M, Keane WM, Santoro M, Fusco A, Rothstein JL. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res 58:5523–5528, 1998[Abstract/Free Full Text]
59. Powell DJ, Russell JP, Li G, Kuo BA, Fidanza V, Huebner K, Rothstein JL. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3^p53–/– mice. Oncogene 20:3235–3246, 2001[CrossRef][ISI][Medline]
60. Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human t